Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist.

William S Wright, Jodine E Messina, Norman R Harris

Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA. wwrigh@lsuhsc.edu

Experimental eye research 2009 Jan

filter terms:

Retinal blood flow has been reported to decrease early in human diabetes as well as in diabetic animal models. The purpose of the present study is to investigate the role of thromboxane receptor binding in the decrease of flow. C57BL/6 mice were injected with streptozotocin (STZ) at 11-12 weeks of age and remained hyperglycemic for 4 weeks. The mice were treated with a selective thromboxane receptor antagonist, GR32191B (vapiprost), in drinking water for the final three weeks at a dose of 1mg/kg/day. In separate experiments, vapiprost was administered only once, as an acute injection 25min prior to the experimental measurements. The measurements included retinal arteriolar and venular diameters and red blood cell (RBC) velocities, from which retinal blood flow was calculated. STZ induced decreases in vascular diameters and RBC velocities, resulting in an approximate 30% decrease in overall retinal blood flow. However, these decreases were not seen in mice given the three-week administration of vapiprost. Acute administration to diabetic mice of 1mg/kg vapiprost, but not 0.1mg/kg, induced arteriolar vasodilation, with the dilation more substantial in smaller feed arterioles. In summary, STZ-induced decreases in retinal blood flow can be attenuated by the thromboxane receptor antagonist vapiprost.

Citation

William S Wright, Jodine E Messina, Norman R Harris. Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist. Experimental eye research. 2009 Jan;88(1):106-12